Abstract:BACKGROUND AND OBJECTIVE Concurrent chemoradiation therapy (CCRT) is the standard treatment for patients with locally advanced nasopharyngeal carcinoma (NPC). The effect of neoadjuvant chemotherapy followed by CCRT has not been determined. Therefore, we conducted 2 phase II studies to evaluate the efficacy and safety of neoadjuvant chemotherapy with a regimen of docetaxel, cisplatin, and 5 fluorouracil (5-Fu) (TPF) followed by radiotherapy and concurrent cisplatin in patients with stage III and IV(A - B) NPC. This article is the preliminary report on treatment related toxicities and response. METHODS Graded according to the 2002 American Joint Committee on Cancer (AJCC) staging criteria, only patients with stage III or IV(A-B) poorly differentiated or undifferentiated NPC (World Health Organization type II/III) were included. We planned to recruit 52 patients with stage III disease and 64 patients with stage IV(A - B) disease. All patients received neoadjuvant chemotherapy with TPF (docetaxel 75 mg/m(2), day 1; cisplatin 75 mg/m(2), day 1; 5 Fu 500 mg/(m2 x day), continuous intravenous infusion for 120 h), every 3 weeks for 3 cycles, followed by weekly cisplatin (40 mg/m(2)) concurrent with radiotherapy. Three dimensional conformal radiotherapy (3D CRT) and intensity modulated radiotherapy (IMRT) were used. Gross disease planning target volume (PTV), high risk and low risk subclinical PTV doses were prescribed at 70-76 Gy, 66-70 Gy, and 60-61.25 Gy at 1.75-2.0 Gy per fraction. The lower neck or supraclavicular fields may be treated with conventional AP/PA fields for a total of 54 Gy at 1.8 Gy per fraction. Patients were evaluated for tumor response after the completion of neoadjuvant chemotherapy, and at 3 months after radiation according to the Response Evaluation Criteria In Solid Tumors (RECIST). The latest version of the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE 3.0) was used for grading all adverse events. RESULTS Fifty nine patients were evaluable for treatment response. Thirty patients had stage III disease and 29 patients had stage IV(A-B). All patients completed RT to the prescribed dose and 2 cycles of neoadjuvant chemotherapy, with 51 patients (86.4%) completing 3 cycles. A total of 50 (84.7%) and 39 patients (66.1%) completed 4 weeks and 5 weeks of cisplatin during CCRT, respectively. The overall response rate in the primary site and the neck region were 94.9% [complete response (CR) in 25.4%] and 100% (CR in 19.6%) after completing neoadjuvant chemotherapy. At 3 months after RT, the CR rates increased to 96.6% and 90.2%, respectively. After a median follow up of 14.3 months, we observed 5 treatment failures and 2 deaths. The 1 year overall survival, distant metastasis free survival, and locoregional relapse free survival rates were 100%, 95.7%, and 97.7%, respectively. The rates of grade 3/4 myelosuppression and anorexia/nausea/vomiting during neoadjuvant chemotherapy were 55.9% and 16.9%, respectively. The corresponding rates were 11.9% and 23.7% during CCRT. Grade 3/4 mucositis, skin desquamation, and xerostomia occurred in 6.8%, 44.1%, and 27.1% of patients, respectively. There were no treatment related deaths. CONCLUSIONS Neoadjuvant chemotherapy with TPF followed by CCRT was well tolerated with a manageable toxicity profile. Preliminary results are encouraging and warrant further investigation.

Preliminary Outcome of Concurrent Chemoradiation Therapy in Patients with Early Stage Extranodal Nasal Type NK/T-cell Lymphoma

Efficacy and toxicities of chemoradiotherapy in the treatment of early stage extranodal nasal-type NK/T-cell lymphoma

[Outcome of Radiotherapy for Low-Risk Early-Stage Patients with Extranodal NK/T-cell Lymphoma, Nasal-Type].

Deep Remission from Induction Chemotherapy Predicts Favorable Long-Term Survivals in Early Stage Extranodal Nasal NK/T-cell Lymphoma Receiving Sequential Chemotherapy and Radiation.

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center

Radiation Therapy Alone Not Inferior to Chemoradiation in the Patients with Stage I Nasal Natural Killer/T-Cell Lymphoma

Neoadjuvant Chemotherapy Followed by Concurrent Chemoradiation for Locally Advanced Nasopharyngeal Carcinoma

Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK /T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study

First-line non–anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: a retrospective analysis from the CLCG

TREATMENT BENEFIT ASSOCIATING WITH NON‐ANTHRACYCLINE CHEMOTHERAPY IN EXTRANODAL NK/T‐CELL LYMPHOMA, NASAL TYPE

Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma.

Treatment Outcomes and Prognostic Factors of Chemotherapy Combined with Radiation Therapy for Patients with Early-Stage Extranodal Natural Killer/T-Cell Lymphoma.

Clinical Features, Prognostic Stratification, and Treatment of Advanced-Stage Non-Nasal Type Extranodal Natural Killer/t-Cell Lymphoma: a Multi-Institutional Real-World Study.

Mild Toxicity and Favorable Prognosis of High–Dose and Extended Involved-Field Intensity-Modulated Radiotherapy for Patients with Early-Stage Nasal NK/T-Cell Lymphoma

Prognostic Factors and Treatment Outcomes for Patients with Stage II Extranodal Nasal-Type Natural Killer/t-Cell Lymphoma of the Upper Aerodigestive Tract

Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity.

Concurrent Chemoradiotherapy with or without Anti-EGFR-Targeted Treatment for Stage II-IVb Nasopharyngeal Carcinoma: Retrospective Analysis with a Large Cohort and Long Follow-up

Long-Term Efficacy of Sequential Dice Chemotherapy with Regional Field Radiation Therapy for Stages I-Ii Natural Killer/T-Cell Lymphoma, Nasal Type: Analysis of 118 Cases

Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.

Preliminary Results of a Phase III Randomized Study Comparing Chemotherapy Neoadjuvantly or Concurrently with Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma

Comparing treatment outcomes of different chemotherapy sequences during radio-chemotherapy for stage N3 nasopharyngeal carcinoma